William G. Wright

Array ( [id] => 11895175 [patent_doc_number] => 09765100 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-19 [patent_title] => 'Nucleoside phosphonate salts' [patent_app_type] => utility [patent_app_number] => 14/672816 [patent_app_country] => US [patent_app_date] => 2015-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11254 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14672816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10346150 [patent_doc_number] => 20150231155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'ONAPRISTONE POLYMORPHIC FORMS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/661382 [patent_app_country] => US [patent_app_date] => 2015-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 4409 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14661382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12283111 [patent_doc_number] => 09931350 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-03 [patent_title] => Anti-infective and osteogenic compositions and methods of use [patent_app_type] => utility [patent_app_number] => 14/645040 [patent_app_country] => US [patent_app_date] => 2015-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 10 [patent_no_of_words] => 15786 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14645040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10373113 [patent_doc_number] => 20150258119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-17 [patent_title] => 'TOPICAL CORTICOSTEROID COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 14/645338 [patent_app_country] => US [patent_app_date] => 2015-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 12308 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14645338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10987486 [patent_doc_number] => 20160184431 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-30 [patent_title] => 'TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID' [patent_app_type] => utility [patent_app_number] => 14/645297 [patent_app_country] => US [patent_app_date] => 2015-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10711 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14645297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10289144 [patent_doc_number] => 20150174142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-25 [patent_title] => 'MANAGEMENT OF BREAKTHROUGH BLEEDING IN EXTENDED HORMONAL CONTRACEPTIVE REGIMENS' [patent_app_type] => utility [patent_app_number] => 14/642096 [patent_app_country] => US [patent_app_date] => 2015-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5044 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14642096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11393895 [patent_doc_number] => 20170014430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'Cycloartenol-Containing Composition' [patent_app_type] => utility [patent_app_number] => 15/124556 [patent_app_country] => US [patent_app_date] => 2015-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8312 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15124556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10346101 [patent_doc_number] => 20150231106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => '3-METHANESULFONYLPROPIONITRILE FOR TREATING INFLAMMATION AND PAIN' [patent_app_type] => utility [patent_app_number] => 14/639781 [patent_app_country] => US [patent_app_date] => 2015-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 9604 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14639781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12790474 [patent_doc_number] => 20180155327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS [patent_app_type] => utility [patent_app_number] => 15/553890 [patent_app_country] => US [patent_app_date] => 2015-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21009 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15553890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10354907 [patent_doc_number] => 20150239912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-27 [patent_title] => 'FATTY ACID AMIDE HYDROLASE INHIBITORS' [patent_app_type] => utility [patent_app_number] => 14/631712 [patent_app_country] => US [patent_app_date] => 2015-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 49762 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14631712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10272585 [patent_doc_number] => 20150157582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-11 [patent_title] => 'METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION' [patent_app_type] => utility [patent_app_number] => 14/628062 [patent_app_country] => US [patent_app_date] => 2015-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 26865 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14628062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11262169 [patent_doc_number] => 09486450 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-08 [patent_title] => 'Hydroxybupropion and related compounds as modulators of drug plasma levels' [patent_app_type] => utility [patent_app_number] => 14/617624 [patent_app_country] => US [patent_app_date] => 2015-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 26922 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14617624 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10324340 [patent_doc_number] => 20150209344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-30 [patent_title] => 'HYDROBROMIDE SALT OF PRIDOPIDINE' [patent_app_type] => utility [patent_app_number] => 14/613845 [patent_app_country] => US [patent_app_date] => 2015-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 5745 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14613845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11362786 [patent_doc_number] => 20170000767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-05 [patent_title] => 'THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS' [patent_app_type] => utility [patent_app_number] => 15/114874 [patent_app_country] => US [patent_app_date] => 2015-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 5400 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15114874 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10256487 [patent_doc_number] => 20150141483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-21 [patent_title] => 'CRYSTALLINE FORMS OF A 3-[2-METHANESULFONYL-1-(4-TRIFLUOROMETHYL-PHENOXY)ETHYL]PYRROLIDINE COMPOUND' [patent_app_type] => utility [patent_app_number] => 14/605187 [patent_app_country] => US [patent_app_date] => 2015-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 15889 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14605187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15449275 [patent_doc_number] => 10548868 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-04 [patent_title] => Metabolism-improving agent comprising rare fatty acid [patent_app_type] => utility [patent_app_number] => 15/113654 [patent_app_country] => US [patent_app_date] => 2015-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10043 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15113654 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12445386 [patent_doc_number] => 09980975 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-29 [patent_title] => Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus [patent_app_type] => utility [patent_app_number] => 14/603224 [patent_app_country] => US [patent_app_date] => 2015-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2361 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14603224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10248422 [patent_doc_number] => 20150133417 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-14 [patent_title] => 'LIPID COMPOSITION' [patent_app_type] => utility [patent_app_number] => 14/601839 [patent_app_country] => US [patent_app_date] => 2015-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6385 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14601839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11793153 [patent_doc_number] => 09402843 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-02 [patent_title] => 'Compositions and methods of using threohydroxybupropion for therapeutic purposes' [patent_app_type] => utility [patent_app_number] => 14/602177 [patent_app_country] => US [patent_app_date] => 2015-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 25136 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14602177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11799620 [patent_doc_number] => 09540410 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-10 [patent_title] => 'Gemcitabine prodrugs and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/599166 [patent_app_country] => US [patent_app_date] => 2015-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 3 [patent_no_of_words] => 25786 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14599166 [rel_patent_id] =>[rel_patent_doc_number] =>)